Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond

• Published in: Blood reviews Vol. 55; p. 100947
• Main Authors: Saha, Chandan, Attwell, Luke, Harrison, Claire N., McLornan, Donal P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2022
• Subjects: AML; JAK2; Leukaemia; MPN; AML; MPN; JAK2; PV; ET; Leukaemia
• ISSN: 0268-960X; 1532-1681
• DOI: 10.1016/j.blre.2022.100947

Accelerated and blast phase myeloproliferative neoplasms present many challenges despite the advent of more novel and targeted therapeutic approaches. Outcome following transformation is frequently dismal, and the only curative approach remains allogeneic stem cell transplantation, applicable to a relatively small proportion of cases. Historically, potential risk factors for transformation from chronic phase disease have been based loosely on increasing age, long disease duration, use of sequential DNA-damaging agents, cytogenetic anomalies and advancing disease burden and limited genomic profiling which frequently reveals disparate signatures. Overall, the risk of these transformation events remains unpredictable, can occur in young individuals even without detectable high risk genomic profiles. Enhanced prognostic approaches would optimise monitoring and early intervention with potential to improve overall outcomes. Within this review we will summarise advances on disease biology, prognostication and molecular annotation and how this may ultimately lead to more rationale, stratified and forward-thinking therapeutic approaches.